SCHEMBL3518485

SCHEMBL3518485

CCCNc1nc2ccc(O)c(C(=O)NCC(=O)OCC)c2nc1-c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 7/20 0.43
HSD17B10 Q99714 2/20 0.43
ALDH1A1 P00352 9/20 0.42
KDM4E B2RXH2 5/20 0.42
LMNA P02545 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PDE5A O76074 1/20 0.40
EGLN3 Q9H6Z9 1/20 0.40
GAA P10253 3/20 0.39
TOP2A P11388 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP2D6 P10635 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CYP3A4 P08684 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3522102 0.90 PPID (0.45) HPGDHSD17B10ALDH1A1LMNANPSR1
SCHEMBL3521577 0.89 EGLN3 (0.50) HPGDALDH1A1KDM4ELMNATDP1
SCHEMBL3517992 0.88 ALDH1A1 (0.49) HPGDHSD17B10ALDH1A1KDM4ELMNA
SCHEMBL3523060 0.83 ALDH1A1 (0.42) HPGDALDH1A1KDM4ELMNATDP1
SCHEMBL3520699 0.79 ALDH1A1 (0.41) HPGDHSD17B10ALDH1A1LMNAEGLN3
SCHEMBL3532071 0.79 ALDH1A1 (0.41) HPGDHSD17B10ALDH1A1LMNAEGLN3
SCHEMBL3518478 0.78 EGLN3 (0.50) HPGDHSD17B10ALDH1A1KDM4ELMNA
SCHEMBL3756784 0.78 NPC1 (0.48) HPGDHSD17B10ALDH1A1KDM4ELMNA
SCHEMBL3755568 0.78 HPGD (0.49) HPGDHSD17B10ALDH1A1KDM4ELMNA
SCHEMBL3516389 0.77 EGLN3 (0.51) ALDH1A1LMNAEGLN3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 HPGD 51/4885HSD17B10 613/4885ALDH1A1 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.